Genotypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy

International Journal of Antimicrobial Agents
Chonlaphat SukasemWasun Chantratita

Abstract

Genotypic testing using TRUGENE was performed for treatment-naive, human immunodeficiency virus type 1 (HIV-1)-infected patients at baseline and after initiation of protease inhibitor (PI)-based highly active antiretroviral therapy (HAART) regimens. The genetic diversity of HIV-1 pol sequences from 92 CRF01_AE and 21 B strains was compared. Subsequently, the impact of polymorphism on resistance to therapy was studied in CRF01_AE-infected (n=29) and subtype B-infected (n=14) patients. At baseline, the differences between CRF01_AE and B strain were mainly observed in the minor mutations L10I/V, M36I and L63P/I/H (P<0.001, chi(2)). In the reverse transcriptase sequence, M41L and T215Y/S were more common in patients infected with subtype B virus (P<0.05, chi(2)). Although all patients treated with PI-based HAART had pre-existing minor mutations, a low prevalence of resistance to PIs was observed (5/43; 11.6%). Moreover, major mutations (D30N and N88D) conferring resistance to PIs were found in patients infected with subtype B strain. In conclusion, polymorphisms at the protease region may not reduce PI susceptibility during treatment. However, this study also revealed the difference in natural mutations among subtypes, which may af...Continue Reading

References

Jan 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·M Kimura
Sep 28, 2001·The Journal of Infectious Diseases·C F PernoUNKNOWN Italian Cohort Naive Antiretroviral (I.CO.N.A.) Study Group
Dec 21, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Li-Yang HsuNicholas I Paton
Mar 28, 2006·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Laurence VergneMartine Peeters
Aug 15, 2006·JAMA : the Journal of the American Medical Association·Scott M HammerUNKNOWN International AIDS Society-USA panel
Jun 14, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Martin S HirschDouglas D Richman

❮ Previous
Next ❯

Citations

Mar 12, 2011·The Protein Journal·Zhigang LiuLadislau C Kovari
Aug 19, 2011·The New England Journal of Medicine·Mark A WainbergBluma G Brenner
Dec 2, 2011·PloS One·Nicole Ngo-Giang-HuongUNKNOWN Program for HIV Prevention and Treatment (PHPT) study group
Feb 13, 2013·Drug Metabolism and Pharmacokinetics·Chonlaphat SukasemWeerawat Manosuthi
Feb 9, 2012·The Indian Journal of Medical Research·N KumarasamySanjay Pujari
Jun 15, 2010·Journal of Molecular Graphics & Modelling·Rosemberg O SoaresMarcelo A Soares
Dec 25, 2012·Biochemical and Biophysical Research Communications·Zhigang LiuLadislau C Kovari
Jan 15, 2013·Biochemical and Biophysical Research Communications·Zhigang LiuLadislau C Kovari
Jul 12, 2013·ISRN Microbiology·Maria Mercedes Santoro, Carlo Federico Perno
Jan 31, 2014·Drug Metabolism and Pharmacokinetics·Chonlaphat SukasemWeerawat Manosuthi
Jul 2, 2009·Journal of the International AIDS Society·Jorge L Martinez-CajasMark A Wainberg
Feb 18, 2010·HIV Therapy·Philip A Chan, Rami Kantor
Dec 15, 2010·AIDS Research and Human Retroviruses·Fernando Flor-ParraPilar Pérez-Romero
Jan 21, 2021·International Journal of Molecular Sciences·Paweł KowalczykIda Franiak-Pietryga

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.